Syndax Pharmaceuticals (SNDX) Total Current Liabilities (2015 - 2026)

Syndax Pharmaceuticals' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $86.2 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 8.86% year-over-year to $86.2 million in Q1 2026; TTM through Mar 2026 was $86.2 million, a 8.86% decrease from a year earlier, with the FY2025 full-year figure at $120.1 million, up 16.0% from the prior year.
• Total Current Liabilities retreated to $86.2 million in Q1 2026 per SNDX's latest filing, from $120.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $120.1 million in Q4 2025 and bottomed at $20.8 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $50.8 million (2024), against an average of $61.6 million.
• Across the five-year window, Total Current Liabilities dropped 27.55% in 2022 and soared 166.03% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $29.1 million in 2022, then surged by 99.88% to $58.1 million in 2023, then surged by 78.24% to $103.5 million in 2024, then climbed by 16.0% to $120.1 million in 2025, then retreated by 28.26% to $86.2 million in 2026.
• Per Business Quant, the three latest SNDX Total Current Liabilities figures stand at $86.2 million (Q1 2026), $120.1 million (Q4 2025), and $114.2 million (Q3 2025).